Review
doi: 10.1016/j.ejca.2007.05.021.
Epub 2007 Jul 10.
The insulin-like growth factor 1 receptor in cancer: old focus, new future
Affiliations
- PMID: 17624760
- DOI: 10.1016/j.ejca.2007.05.021
Item in Clipboard
Review
The insulin-like growth factor 1 receptor in cancer: old focus, new future
Eur J Cancer.
2007 Sep.
Abstract
The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.
Similar articles
-
Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.Curr Opin Investig Drugs. 2009 Oct;10(10):1032-40. Curr Opin Investig Drugs. 2009. PMID: 19777391 Review.
-
The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy.Growth Horm IGF Res. 2004 Aug;14(4):287-95. doi: 10.1016/j.ghir.2004.02.004. Growth Horm IGF Res. 2004. PMID: 15231297 Review.
-
State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.Discov Med. 2011 Feb;11(57):144-53. Discov Med. 2011. PMID: 21356169 Review.
-
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.Mol Cell Endocrinol. 2011 Sep 15;344(1-2):1-24. doi: 10.1016/j.mce.2011.07.002. Epub 2011 Jul 18. Mol Cell Endocrinol. 2011. PMID: 21782884 Review.
-
Insulin-Like Growth Factor (IGF) family and prostate cancer.Crit Rev Oncol Hematol. 2006 May;58(2):124-45. doi: 10.1016/j.critrevonc.2005.10.003. Epub 2006 Jan 18. Crit Rev Oncol Hematol. 2006. PMID: 16387509 Review.
Cited by
-
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Cancers (Basel). 2011 Jul 26;3(3):3029-54. doi: 10.3390/cancers3033029. Cancers (Basel). 2011. PMID: 24212944 Free PMC article.
-
Impact of targeting insulin-like growth factor signaling in head and neck cancers.Growth Horm IGF Res. 2013 Oct;23(5):135-40. doi: 10.1016/j.ghir.2013.06.001. Epub 2013 Jun 29. Growth Horm IGF Res. 2013. PMID: 23816396 Free PMC article. Review.
-
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway.Mol Cancer. 2018 Feb 19;17(1):28. doi: 10.1186/s12943-018-0807-z. Mol Cancer. 2018. PMID: 29455671 Free PMC article. Review.
-
Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus.Medicine (Baltimore). 2017 Mar;96(12):e6393. doi: 10.1097/MD.0000000000006393. Medicine (Baltimore). 2017. PMID: 28328831 Free PMC article.
-
Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5. Mol Imaging Biol. 2013. PMID: 22875335 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
